What InGeneron does

InGeneron is a privately held, clinical-stage biotechnology company developing autologous cell-based therapies for orthopedic conditions. The company was founded in 2009 (per SEC filing) and is headquartered in Houston, Texas, with a German subsidiary (InGeneron GmbH) in Munich and a US presence in Cambridge, Massachusetts. Its core product is the Transpose Ultra System, a point-of-care cell processing platform consisting of a centrifuge-based Processing Unit, sterile single-use disposables, and the proprietary Matrase enzymatic reagent. The system isolates adipose-derived regenerative cells (ADRCs)—including vascular-associated pluripotent stem cells (vaPS cells), mesenchymal stem cells, progenitor cells, and macrophages—from a patient's own fat tissue in approximately 90 minutes, enabling same-day injection into damaged tissue without cell culturing or external manipulation.

The company serves patients with chronic orthopedic conditions such as partial-thickness rotator cuff tears, knee osteoarthritis, wrist osteoarthritis, facet joint syndrome, and chronic wounds, offering an alternative to corticosteroid injections and invasive surgery. Its primary customer segments are orthopedic surgeons, sports medicine physicians, and pain management specialists, supported by academic medical centers (Emory University, Ludwig-Maximilians University, Tulane University, Isarklinikum Munich) that conduct sponsored and investigator-initiated trials. In the United States, the Transpose Ultra System is available only for investigational use under FDA-approved clinical trials; in the European Union, it is CE-marked under EU MDR (EU) 2017/745 and commercially available, with revenue generated through hardware and consumable sales to trained medical facilities.

InGeneron has been financed primarily by Sanford Health, which has invested up to $43 million across Series D tranches (2017 and 2019), with additional undisclosed rounds totaling approximately $4.7 million. The company has secured CPT Category III codes (0717T, 0718T) for its rotator cuff therapy, a CE Certificate under EU MDR (issued January 2026), and ISO 13485 certification, and has published long-term clinical data including 3.4-year durable benefit in rotator cuff tears and a 480-patient Phase III knee osteoarthritis trial (MILES) conducted at Emory University.

Name

InGeneron

Legal name

InGeneron, Inc.

Website

https://ingeneron.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

InGeneron is a clinical-stage biotechnology company developing the Transpose Ultra System, a point-of-care platform that isolates adipose-derived regenerative cells for same-day autologous treatment of orthopedic conditions such as rotator cuff tears, knee osteoarthritis, and facet joint syndrome. It serves orthopedic surgeons and pain management specialists via FDA-approved US trials and CE-marked EU sales.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Autologous cell therapy
• Regenerative medicine devices
• Adipose-derived cell processing
• Orthopedic cell therapy
• Point-of-care cell isolation

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Transpose Ultra System Commercialization: InGeneron generates revenue through the sale of its CE-marked Transpose Ultra System (processing unit, sterile kits, and Matrase reagent) to healthcare providers and clinics in the European Union where it is commercially available. In the US, the system is for investigational use only pending FDA approval.
2. Cell Therapy Treatments: Future revenue anticipated from cell therapy treatments performed using the Transpose Ultra System at point-of-care once FDA approval is obtained for specific orthopedic indications.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

InGeneron develops and commercializes the Transpose Ultra® System, a CE-marked medical device platform that enables physicians to isolate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue at point-of-care in under 90 minutes for same-day autologous treatment. The system comprises a Processing Unit (centrifuge), sterile disposables, and the proprietary Matrase™ enzymatic reagent. It is used to treat chronic orthopedic conditions including partial-thickness rotator cuff tears, wrist osteoarthritis, facet joint syndrome, and knee osteoarthritis. The system is commercially available in the EU under EU MDR and available for investigational use in the US through FDA-approved clinical trials.

Product overview

InGeneron offers the Transpose Ultra System as its core product platform for autologous cell therapy. The system consists of three main components: the Processing Unit (a centrifuge), a set of sterile disposables, and the proprietary Matrase enzyme reagent. Together, these components enable physicians to isolate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue at point-of-care and reinject them into damaged tissue the same day. The Transpose Ultra System is CE-marked and commercially available in the EU under MDR regulation, while the same technology is available in the US only for investigational use under FDA-approved clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• Transpose Ultra® System: A cell therapy platform consisting of a processing unit, disposables, and Matrase enzymatic reagent for isolating regenerative cells from adipose tissue at point-of-care.
• Transpose® RT System

Products and services

• Transpose Ultra® System A CE-marked cell therapy platform consisting of a Processing Unit (centrifuge), sterile disposable kit, and the proprietary Matrase enzyme reagent. It enables physicians to isolate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue at point-of-care in under 90 minutes for same-day autologous reinjection into damaged tissue. Commercially available in the EU for clinical use; available for investigational use only in the US under FDA-approved clinical trials.
• Matrase™ Enzymatic Reagent A proprietary enzymatic reagent used during Transpose Ultra processing to optimize regenerative cell yield by facilitating efficient enzymatic extracellular degradation that liberates ADRCs from their surrounding matrix. Sold as a consumable component of the Transpose Ultra System workflow.

Quantifiable outcome

• Mean ASES scores significantly higher in ADRC group vs corticosteroid group at 24 and 52 weeks post-treatment for partial-thickness rotator cuff tears
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Isarklinikum MunichcoreStrategic or Co-development PartnerGerman hospital partner conducting investigator-initiated clinical studies including facet joint syndrome case series and preclinical research. Dr. Ralf Rothörl leads studies at the Department of Neurosurgery.
• German Accelerator Life Sciences (GALS)minorStrategic or Co-development PartnerProgram supported by German Federal Ministry for Economic Affairs and Energy (BMWi). Provides mentorship, industry network access, and support for US market development. Company established presence in Cambridge, MA through this program.
• Emory UniversitycoreStrategic or Co-development PartnerSponsored the MILES Phase III 480-patient knee osteoarthritis trial published in Nature Medicine (2023). Investigated InGeneron's cell therapy compared to corticosteroid injections and other orthobiologics.
• Ludwig-Maximilians University of MunichcoreStrategic or Co-development PartnerResearch collaboration with Department of Anatomy II led by Dr. Christoph Schmitz (Advisory Medical Director of InGeneron). Multiple co-authored publications on vaPS cells, cell composition studies, and clinical outcomes.
• Tulane UniversitycoreStrategic or Co-development PartnerLong-standing research collaboration with Dr. Eckhard Alt (Director of Stem Cell Research at Tulane). Over 20 years of basic research supporting company's technology platform.
• Intertek Medical Notified Body ABcoreTechnology or IntegrationEU Notified Body (2862) that conducted extensive technical documentation review and ISO 13485 Quality Management System audits to issue CE Certificate under EU MDR 2017/745 for Transpose Ultra System.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• BioRestorative Therapies: BioRestorative Therapies is developing autologous stem cell therapies, including BRTX-100 for chronic lumbar disc disease and a brown fat program. Both companies work on point-of-care autologous cell therapy in musculoskeletal indications, though BioRestorative is at an earlier clinical stage.
• Histogenics: Histogenics developed NeoCart, an autologous cell-based cartilage repair technology for knee cartilage defects. Both companies pursued FDA pathways for autologous cell therapy in orthopedic cartilage indications, providing direct regulatory and clinical comparison.
• Regeneus: Regeneus is an Australian clinical-stage company developing autologous adipose-derived cell therapies (Progenza) for knee osteoarthritis. The adipose-derived cell source and orthopedic indication overlap directly with InGeneron's ADRC platform.

Direct peers

• Lipogems International: Lipogems commercializes a CE-marked, FDA-cleared point-of-care system for processing adipose tissue into injectable graft material, competing directly with InGeneron's Transpose Ultra System in the orthopedic regenerative space. Both target same-day autologous fat-derived therapy for orthopedic indications.
• Vericel: Vericel markets MACI, an autologous cell-based therapy for cartilage repair in the knee, and is the closest direct commercial-stage analog to InGeneron's orthopedic regenerative cell therapy model. Both companies commercialize point-of-care or lab-processed autologous cell therapies for orthopedic indications in the US and EU.
• Mesoblast: Mesoblast develops allogeneic cell therapies including remestemcel-L and rexlemestrocel-L for orthopedic and inflammatory indications. Both companies pursue regenerative cell therapy approvals in musculoskeletal disease, sharing endpoint design, regulatory pathways, and orthopedic surgeon customer base.
• Cesca Therapeutics (now part of ThermoGenesis): Cesca Therapeutics developed point-of-care cell processing systems (including the MarrowXpress and other surgical recovery systems) for autologous cell therapy in orthopedic applications. Both companies pioneered automated bedside cell isolation devices for orthopedic surgeons.

Broad incumbents

• Arthrex: Arthrex is the dominant orthopedic sports medicine device company, offering PRP, BMAC, and adipose-derived cell processing systems (e.g., Arthrex Angel System) used by orthopedic surgeons. It is a broad incumbent shaping the orthobiologics competitive landscape that InGeneron must enter.
• Zimmer Biomet: Zimmer Biomet is a major orthopedic device company with a portfolio spanning joint reconstruction, sports medicine, and orthobiologics including PRPs and cellular therapies. As a broad incumbent, it competes for surgeon adoption of regenerative technologies in the same orthopedic indications InGeneron targets.

Others

• CellGenix: CellGenix is a supplier of cell culture reagents, cytokines, and GMP manufacturing services for cell and gene therapy developers. While not a direct competitor, it is an adjacent supplier enabling the regenerative cell therapy ecosystem in which InGeneron competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/InGeneronInc
• YouTubeyoutube.com/channel/UCxyRKmBicbG2WzPnTJuF4Aw
• Facebookfacebook.com/InGeneron-138615332852795
• LinkedInlinkedin.com/company/ingeneron-incorporation

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InGeneron